For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

The high school sports year has come to a close, but a La Costa Canyon High School freshman swimmer is reshaping what is ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) has announced positive and sustained results from its Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. The trial, known ...

Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...

(Exclusive) She also notes that babies with dwarfism or achondroplasia can have "larger than normal" heads. From a birthing perspective, Liz admits that carrying Leighton was "just more bearable ...

Bridgebio Pharma Inc.’s data from the phase II study with infigratinib in achondroplasia “swings the pendulum of debate ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

BioMarin Pharmaceutical (BMRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.